A survey of physicians show a one-third reduction in harmful outcomes to be a clinically important difference for statin therapy

Physicians were consistent in their choice of MCID for statin therapy across vascular events. They required a larger benefit of statin therapy for patients at a lower baseline risk (5%) of developing a vascular event before they would recommend treatment.